Skip to main content

Table 3 Baseline characteristics metastatic melanoma

From: Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital’s experience

  Clinical benefit (n=8) No clinical benefit (n=29) P-value
Age 54.5 (49.0-59.25) 56.0 (43.5-64.5) .986*
Male 8 (100%) 22 (75.9%) .308
BRAF Mutated 2/5 (40%) 9/19 (47.4%) 1.00
Baseline ALC 1.50 (0.975-1.775) 1.30 (0.95-1.80) .842*
LDH 203.5 (164.0-415.75) 244.0 (187.0-542.5) .251*
Ulceration 2/6 (33.3%) 6/20 (30.0%) 1.00
Prior Treatments 0/8 (0%) 7/29 (24.1%) 0.318
Metastatic Subsets
IVA 2 (25%) 4 (13.8%) .591
IVB 1 (12.5%) 6 (20.7%) 1.0
IVC 5 (62.5%) 19 (65.5%) 1.0
  1. Fisher’s Exact test (reported as frequency(percent)).
  2. * Mann–Whitney U (reported as median (interquartile range)).
  3. ALC: Absolute Lymphocyte Count.
  4. LDH: Lactate Dehydrogenase.